<DOC>
	<DOC>NCT00375648</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of 4 mg zoledronic acid administered intravenously every 3-4 weeks in the treatment of bone metastases-related pain in patients with prostate cancer.</brief_summary>
	<brief_title>Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metastases-related Pain in Patients With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Histologically proven adenocarcinoma of the prostate Bonescan documented metastases Age &gt; 18 years Noncontrolled bone pain despite systemic antitumor therapy (hormone or chemotherapy) initiated at least 4 weeks before inclusion Life expectancy &gt; 3 months Written informed consent New systemic antitumor therapy initiated less than 4 weeks before study entry or predictable need for starting a new treatment within 8 weeks Radiation therapy on bone target lesions or bonetargeted isotope therapy (strontium or samarium) completed less than 4 weeks before study entry Bisphosphonate therapy within 8 weeks before study entry Abnormal renal function (serum creatinine &gt; 2 x the upper normal limit or creatinine clearance &lt; 30 ml/min) Corrected serum calcium &gt; 3 mmol/L or &lt; 2 mmol/L Clinically relevant hypersensitivity to zoledronic acid, or another bisphosphonate, or one component present in the formulation of the study drug Severe concomitant medical condition that could hamper patient's quality of life or influence the interpretation of pain Patients unable to fill in a questionnaire (neurologic or psychiatric conditions, illiteracy, etc.) Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Prostate</keyword>
	<keyword>Cancer</keyword>
	<keyword>Bone metastases</keyword>
	<keyword>Zoledronic acid</keyword>
	<keyword>Bone metastases-related pain</keyword>
	<keyword>Prostate cancer</keyword>
</DOC>